1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required) is sponsored by National Cancer Institute (NCI). This opportunity from the National Cancer Institute (NCI) is for the Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations. This is a cooperative agreement (UM1) and requires a clinical trial.
Get alerted about grants like this
Get emailed when new opportunities from “National Cancer Institute (NCI)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required) The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required) Agency: National Institutes of Health Assistance Listings: 93. 395 -- Cancer Treatment Research Last Updated: May 8, 2026 View version history on Grants.
gov Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications from institutions/organizations that propose to maintain or establish Lead Academic Organizations (LAOs) as part of the NCI Experimental Therapeutics Clinical Trials Network (ETCTN).
ETCTN LAOs will design, develop, monitor, conduct, and analyze early phase clinical trials (e.g., phase 0, phase 1, phase 2, pilot, and other experimental therapeutic clinical trials) involving agents under regulatory sponsorship for New Investigational Drug (IND) applications held by NCI's Division of Cancer... Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).
Each ETCTN LAO will participate in clinical trials it leads as well as clinical trials led by other LAOs in the network.
Federally recognized Native American tribal governments Special district governments Public and Indian housing authorities City or township governments Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Nonprofits non-higher education with 501(c)(3) Independent school districts Private institutions of higher education Public and state institutions of higher education For-profit organizations other than small businesses Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Eligible institution/organization for the purposes of this application is defined as an academic center/organization in the United States or Canada providing direct medical care to patients that is considered one integral organizational entity under a single financial management system and governance structure.
A center/organization (e.g., an academic hospital and/or academic clinic program) for this application is distinguished from large medical centers whose primary mission is patient care. In addition to patient care, academic centers/organizations have comprehensive medical training programs, investigational pharmacies, advanced imaging facilities, and preclinical laboratories that perform basic research.
The only Non-domestic (non-U.S.) Entities (Foreign Institutions) allowed in response to this NOFO are Canadian Institutions. Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Grantor contact information Email: NCIETCTNRFA@mail. nih.
gov Email: NCIETCTNRFA@mail. nih. gov Email: NCIETCTNRFA@mail.
nih. gov File name Description Last updated RFA-CA-27-016-Full-Announcement. html RFA-CA-27-016-Full-Announcement.
html Link to additional information Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity :
According to the current listing, eligibility includes: Public and private nonprofit organizations and institutions, including institutions of higher education, hospitals, and nonprofit research institutes. Confirm the full requirements in the official notice before applying.
The published deadline was July 1, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI). This Notice of Funding Opportunity (NOFO) from the NCI solicits applications for Research Units (RUs) to conduct research on the early detection of pancreatic ductal adenocarcinoma (PDAC) and the characterization of its precursor lesions.